The University of Southampton
University of Southampton Institutional Repository

Use of the FebriDx® host-response point-of-care test may reduce antibiotic use for respiratory tract infections in primary care: a mixed-methods feasibility study

Use of the FebriDx® host-response point-of-care test may reduce antibiotic use for respiratory tract infections in primary care: a mixed-methods feasibility study
Use of the FebriDx® host-response point-of-care test may reduce antibiotic use for respiratory tract infections in primary care: a mixed-methods feasibility study

INTRODUCTION: FebriDx® is a CE-marked, single-use point-of-care test with markers for bacterial [C-reactive protein (CRP)] and viral [myxovirus resistance protein A (MxA)] infection, using finger-prick blood samples. Results are available after 10-12 min. We explored the usability and potential impact of FebriDx® in reducing antibiotic prescriptions for lower respiratory tract infection (LRTI) in primary care, and the feasibility of conducting a randomized controlled trial (RCT).

METHODS: Patients (aged ≥1 year) with LRTI deemed likely to receive antibiotic prescription were recruited at nine general practices and underwent FebriDx® testing. Data collection included FebriDx® results, antibiotic prescribing plan (before and after testing) and re-consultation rates. Staff completed System Usability Scale questionnaires.

RESULTS: From 31 January 2023 to 9 June 2023, 162 participants participated (median age 57 years), with a median symptom duration of 7 days (IQR 5-14). A valid FebriDx® result was obtained in 97% (157/162). Of 155 patients with available results, 103 (66%) had no detectable CRP or MxA, 28 (18%) had CRP only, 5 (3%) had MxA only, and 19 (12%) had both CRP and MxA. The clinicians' stated management plan was to prescribe antibiotics for 86% (134/155) before testing and 45% (69/155) after testing, meaning a 41% (95% CI: 31%, 51%) difference after testing, without evidence of increased re-consultation rates. Ease-of-use questionnaires showed 'good' user-friendliness.

CONCLUSIONS: Use of FebriDx® to guide antibiotic prescribing for LRTI in primary care was associated with a substantial reduction in prescribing intentions. These results support a fully powered RCT to confirm its impact and safety.

Adolescent, Adult, Aged, Anti-Bacterial Agents/therapeutic use, Biomarkers/blood, C-Reactive Protein/analysis, Child, Feasibility Studies, Female, Humans, Male, Middle Aged, Point-of-Care Testing, Primary Health Care, Respiratory Tract Infections/drug therapy, Young Adult
0305-7453
1441-1449
Wilcox, Christopher R.
e2c4c36a-e2e5-43a5-9fd6-7198cc15dd53
Odeh, Nour
b2a36d93-58c1-4581-8172-6d6ca8d54643
Clark, Tristan W.
712ec18e-613c-45df-a013-c8a22834e14f
Muller, Ingrid
2569bf42-51bd-40da-bbfd-dd4dbbd62cad
Becque, Taeko
ecd1b4d5-4db8-4442-81c2-04aa291cf2fd
Todd, Alexander
fad39ae1-5552-4d51-b254-4f84030c7c07
Islam, Nazrul
e5345196-7479-438f-b4f6-c372d2135586
Little, Paul
1bf2d1f7-200c-47a5-ab16-fe5a8756a777
Davies, Firoza
dfbad70e-7928-4b1c-a26d-9a10281b8833
McGavin, John
d5270e50-7abc-4b77-981d-ac68d3110b4a
Francis, Nick
9b610883-605c-4fee-871d-defaa86ccf8e
et al.
Wilcox, Christopher R.
e2c4c36a-e2e5-43a5-9fd6-7198cc15dd53
Odeh, Nour
b2a36d93-58c1-4581-8172-6d6ca8d54643
Clark, Tristan W.
712ec18e-613c-45df-a013-c8a22834e14f
Muller, Ingrid
2569bf42-51bd-40da-bbfd-dd4dbbd62cad
Becque, Taeko
ecd1b4d5-4db8-4442-81c2-04aa291cf2fd
Todd, Alexander
fad39ae1-5552-4d51-b254-4f84030c7c07
Islam, Nazrul
e5345196-7479-438f-b4f6-c372d2135586
Little, Paul
1bf2d1f7-200c-47a5-ab16-fe5a8756a777
Davies, Firoza
dfbad70e-7928-4b1c-a26d-9a10281b8833
McGavin, John
d5270e50-7abc-4b77-981d-ac68d3110b4a
Francis, Nick
9b610883-605c-4fee-871d-defaa86ccf8e

Wilcox, Christopher R., Odeh, Nour and Clark, Tristan W. , et al. (2024) Use of the FebriDx® host-response point-of-care test may reduce antibiotic use for respiratory tract infections in primary care: a mixed-methods feasibility study. Journal of Antimicrobial Chemotherapy, 79 (6), 1441-1449, [dkae127]. (doi:10.1093/jac/dkae127).

Record type: Article

Abstract

INTRODUCTION: FebriDx® is a CE-marked, single-use point-of-care test with markers for bacterial [C-reactive protein (CRP)] and viral [myxovirus resistance protein A (MxA)] infection, using finger-prick blood samples. Results are available after 10-12 min. We explored the usability and potential impact of FebriDx® in reducing antibiotic prescriptions for lower respiratory tract infection (LRTI) in primary care, and the feasibility of conducting a randomized controlled trial (RCT).

METHODS: Patients (aged ≥1 year) with LRTI deemed likely to receive antibiotic prescription were recruited at nine general practices and underwent FebriDx® testing. Data collection included FebriDx® results, antibiotic prescribing plan (before and after testing) and re-consultation rates. Staff completed System Usability Scale questionnaires.

RESULTS: From 31 January 2023 to 9 June 2023, 162 participants participated (median age 57 years), with a median symptom duration of 7 days (IQR 5-14). A valid FebriDx® result was obtained in 97% (157/162). Of 155 patients with available results, 103 (66%) had no detectable CRP or MxA, 28 (18%) had CRP only, 5 (3%) had MxA only, and 19 (12%) had both CRP and MxA. The clinicians' stated management plan was to prescribe antibiotics for 86% (134/155) before testing and 45% (69/155) after testing, meaning a 41% (95% CI: 31%, 51%) difference after testing, without evidence of increased re-consultation rates. Ease-of-use questionnaires showed 'good' user-friendliness.

CONCLUSIONS: Use of FebriDx® to guide antibiotic prescribing for LRTI in primary care was associated with a substantial reduction in prescribing intentions. These results support a fully powered RCT to confirm its impact and safety.

Text
PREFIX_final accepted version - Accepted Manuscript
Download (1MB)
Text
dkae127 - Version of Record
Available under License Creative Commons Attribution.
Download (1MB)

More information

Accepted/In Press date: 2 April 2024
Published date: 1 June 2024
Additional Information: Publisher Copyright: © 2024 The Author(s). Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
Keywords: Adolescent, Adult, Aged, Anti-Bacterial Agents/therapeutic use, Biomarkers/blood, C-Reactive Protein/analysis, Child, Feasibility Studies, Female, Humans, Male, Middle Aged, Point-of-Care Testing, Primary Health Care, Respiratory Tract Infections/drug therapy, Young Adult

Identifiers

Local EPrints ID: 490164
URI: http://eprints.soton.ac.uk/id/eprint/490164
ISSN: 0305-7453
PURE UUID: 9a5a5267-c994-4b9b-b3a6-0e90886a6cd1
ORCID for Tristan W. Clark: ORCID iD orcid.org/0000-0001-6026-5295
ORCID for Ingrid Muller: ORCID iD orcid.org/0000-0001-9341-6133
ORCID for Taeko Becque: ORCID iD orcid.org/0000-0002-0362-3794
ORCID for Nazrul Islam: ORCID iD orcid.org/0000-0003-3982-4325
ORCID for Paul Little: ORCID iD orcid.org/0000-0003-3664-1873
ORCID for Nick Francis: ORCID iD orcid.org/0000-0001-8939-7312

Catalogue record

Date deposited: 16 May 2024 16:37
Last modified: 12 Jul 2024 04:01

Export record

Altmetrics

Contributors

Author: Nour Odeh
Author: Ingrid Muller ORCID iD
Author: Taeko Becque ORCID iD
Author: Alexander Todd
Author: Nazrul Islam ORCID iD
Author: Paul Little ORCID iD
Author: Firoza Davies
Author: John McGavin
Author: Nick Francis ORCID iD
Corporate Author: et al.

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×